Sanofi stock trades around mid-August lows as Q2 2026 earnings and guidance frame a cautious outlook

Sanofi (FR0000127771) stock is holding close to recent mid-August levels, with its US-listed shares last indicated at $43.72 as of the August 14, 2026 close, while investors digest Q2 2026 revenue, earnings and guidance signals and a measured upside in the current analyst consensus.

Q2 2026 earnings give a mixed signal

Per a recent US market data overview as of August 14, 2026, Sanofi reported Q2 FY26 revenue of $12.3 billion and earnings of $343 million, giving investors a snapshot of the latest quarter’s scale and profitability in big pharma.

The same Q2 FY26 data set shows normalized GAAP earnings per share for Sanofi at $1.20 versus a consensus estimate of $1.14, indicating a positive earnings surprise of $0.06 per share for the quarter and underlining that profitability came in ahead of expectations even as revenue growth stayed disciplined.

Analyst consensus and price targets

A broader analyst overview compiled as of August 14, 2026 assigns Sanofi an average rating score of 2.40 on a scale where lower scores indicate stronger conviction, based on 2 strong buy ratings, 3 buy ratings, 9 hold ratings and 1 sell rating, capturing a cautiously constructive stance from the sell-side community.

The same consensus framework points to a price target of $49.50 for Sanofi’s US-listed shares, implying an upside of 13.2% from the most recent closing price of $43.72 on August 14, 2026 and quantifying the gap that analysts currently see between market pricing and their valuation views.

Cross-market trading levels and dividend context

Market data for Sanofi’s European listing as of August 14, 2026 shows a last closing price of €75.55 per share, providing a useful cross-currency and cross-market reference point alongside the $43.72 US price and highlighting that Sanofi trades on both sides of the Atlantic.

Additional quote information for Sanofi’s US listing indicates a dividend yield of 5.46% as of mid-August 2026, which positions the stock as a meaningful income vehicle within healthcare, while European market data lists a dividend yield of 5.39% on €75.55, reinforcing the income profile for investors who access the shares via Frankfurt.

Sector pressure on European pharma

A broader European market update dated August 17, 2026 notes that pharmaceutical stocks in the region came under pressure, with Sanofi declining 1.2% in the session alongside a 3.2% drop in a key peer, illustrating that the share price action is influenced not only by company-specific earnings but also by sector-wide risk appetite.

For Sanofi, this European sector softness means that the mid-August price levels around $43.72 in the US and €75.55 in Europe sit against a backdrop of cautious sentiment toward large-cap biotech and pharma, even though the company delivered a modest earnings beat in Q2 FY26.

Dupixent and specialty portfolio as growth drivers

Sanofi’s growth narrative continues to lean heavily on specialty medicines and key biologics such as Dupixent, which remain central to its strategy of balancing mature primary care franchises with higher-margin innovative therapies targeting immunology, allergy and dermatology indications.

In Q2 FY26, the earnings and revenue mix reflects that dynamic, with the normalized GAAP EPS beat of $0.06 versus consensus showing that operating leverage and product mix supported profitability even as Sanofi navigated pricing pressures and competitive challenges across its broader pharmaceutical portfolio.

Representative product: Lantus

One representative product in Sanofi’s portfolio is Lantus, a long-acting insulin used in the management of diabetes that has been a cornerstone therapy in endocrinology and primary care and continues to contribute meaningfully to the company’s global revenue base despite increasing competition from biosimilars.

Sanofi stock and current valuation levels

As of August 14, 2026, Sanofi’s US-listed shares last closed at $43.72, with an extended-hours indication of $43.80, while the European listing was quoted at €75.55 per share, giving investors a clear sense of the current valuation zone ahead of the next earnings update.

Fact box

Company: Sanofi S.A.

ISIN: FR0000127771

Ticker: SNY

Exchange: NASDAQ (US ADR), primary listing in Europe

Price (as of August 14, 2026, 4:00 p.m. ET): $43.72 USD

Market cap: $104.76 billion (as of August 14, 2026)

Sector / Industry: Healthcare / Pharmaceuticals

Index membership: major European blue-chip indices